| the findings suggested that miR-26a may function as a tumor suppressor in prostate cancer by targeting Wnt5a. | prostate, |
| Data showed downregulation of miR-26a and miR-26b in prostate cancer and suggested them as tumor suppressors. They both targeted the 3_UTR of LARP1. | prostate, |
| Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma | HNSC, |
| Results show that miR-26a and miR-26b were significantly downregulated in renal cell carcinoma clinical specimens and appeared to function as tumor suppressors through regulation of collagen cross-linking enzymes, LOXL2 and PLOD2, both of which function as oncogenes in this disease. | kidney, |
| Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer | colorectal, |
| MiR-26a functions as a tumor suppressor in ambient particulate matter-bound metal-triggered lung cancer.LIN28B was a direct target of miR-26a. | lung, |
| The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells | liver, |
| Study demonstrates that TCF12 is a direct target of miR26a, and upregulation of miR26a resulted in TCF12 inhibition in epithelial ovarian cancer (OC) cells. Furthermore, the proliferation, migration and invasion were inhibited and apoptosis was induced by miR26a upregulation in OC cells. These results indicated that miR26a may act as a tumor suppressor in OC, and TCF12 targeting by miR26a. | ovarian, |
| This study, we performed a comprehensive analysis of putative human miRNA oncogenes and tumor suppressors. We found that miRNA oncogenes and tumor suppressors clearly show different patterns in function, evolutionary rate, expression, chromosome distribution, molecule size, free energy, transcription factors, and targets. | None |
| data suggest that miR-26a functions as a tumor suppressor in GC development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for GC. | None |
| studies reveal a tumor suppressor role for miR-26 in intestinal cancer | None |
| we propose that epigenetic silencing of miR26A1 is required for the maintenance of increased levels of EZH2, which in turn translate into a worse outcome, as shown in CLL, highlighting miR26A1 as a tumor suppressor miRNA. | None |
| Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma | None |
| MiR-26a regulation of FBXO11 expression exhibited an oncogenic role in hepatocellular carcinoma cells. | liver, |